Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arava physical function claim, liver toxicity warning

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA approves Aventis' rheumatoid arthritis agent Arava (leflunomide) for improvement of physical function in RA patients. The June 13 approval also updates labeling to include a bolded warning on severe liver injury and more explicit monitoring instructions. The update is in contrast to the March 5 Arthritis Drugs Advisory Committee's recommendation that the agent's previous liver toxicity warning was sufficient. The committee voted 11-0 (two abstentions) for approval of the physical function claim (1Pharmaceutical Approvals Monthly March 1, 2003, In Brief)...

Related Content

Arava committee review





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts